NYC Startup Syntimmune Names Former Biogen Exec as New CEO Post author:Sam Post published:January 2, 2018 Post category:BioPharma Syntimmune has appointed Jean-Paul Kress as president and CEO. Source: BioSpace You Might Also Like Biohaven Eyes $100 Million IPO to Bankroll Trials of Shelved AstraZeneca PLC, Bristol-Myers Squibb Drugs April 9, 2017 Lysogene Reinforces Its Management Team With The Nomination Of As Chief Operating Officer May 16, 2017 Orchard Therapeutics Scoops Up $110M in Funding to Advance "Bubble Boy Syndrome" Gene Therapy December 19, 2017
Biohaven Eyes $100 Million IPO to Bankroll Trials of Shelved AstraZeneca PLC, Bristol-Myers Squibb Drugs April 9, 2017
Lysogene Reinforces Its Management Team With The Nomination Of As Chief Operating Officer May 16, 2017
Orchard Therapeutics Scoops Up $110M in Funding to Advance "Bubble Boy Syndrome" Gene Therapy December 19, 2017
